These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21487529)

  • 1. Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literature.
    Agostino NM; Ahmed B; Popescu D; Gheith S
    Int J Clin Exp Pathol; 2011 Mar; 4(3):322-6. PubMed ID: 21487529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired EVI1 rearrangement involved in the transformation from 5q- syndrome to pre-B lymphocytic leukemia in a Chinese patient.
    Liu D; Chen S; Pan J; Zhu M; Wu N; Zhu F; Chen Z
    Int J Hematol; 2012 Dec; 96(6):806-9. PubMed ID: 23054648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 5q- syndrome: biology and treatment.
    Padron E; Komrokji R; List AF
    Curr Treat Options Oncol; 2011 Dec; 12(4):354-68. PubMed ID: 21964863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
    Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
    Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
    Mallo M; Cervera J; Schanz J; Such E; García-Manero G; Luño E; Steidl C; Espinet B; Vallespí T; Germing U; Blum S; Ohyashiki K; Grau J; Pfeilstöcker M; Hernández JM; Noesslinger T; Giagounidis A; Aul C; Calasanz MJ; Martín ML; Valent P; Collado R; Haferlach C; Fonatsch C; Lübbert M; Stauder R; Hildebrandt B; Krieger O; Pedro C; Arenillas L; Sanz MÁ; Valencia A; Florensa L; Sanz GF; Haase D; Solé F
    Leukemia; 2011 Jan; 25(1):110-20. PubMed ID: 20882045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
    Ureshino H; Kizuka H; Kusaba K; Sano H; Nishioka A; Shindo T; Kubota Y; Ando T; Kojima K; Kimura S
    Int J Hematol; 2017 May; 105(5):692-696. PubMed ID: 27914067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5q-anomaly.
    Van den Berghe H; Vermaelen K; Mecucci C; Barbieri D; Tricot G
    Cancer Genet Cytogenet; 1985 Jul; 17(3):189-255. PubMed ID: 3891074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.
    Jaju RJ; Jones M; Boultwood J; Kelly S; Mason DY; Wainscoat JS; Kearney L
    Genes Chromosomes Cancer; 2000 Nov; 29(3):276-80. PubMed ID: 10992302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
    Ebert BL
    Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion.
    Feurstein S; Thomay K; Hofmann W; Buesche G; Kreipe H; Thol F; Heuser M; Ganser A; Schlegelberger B; Göhring G
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of transformation of childhood myelodysplastic syndrome to acute lymphoblastic leukemia.
    Koh YR; Cho EH; Park SS; Park MY; Lee SM; Kim IS; Lee EY
    Ann Lab Med; 2013 Mar; 33(2):130-5. PubMed ID: 23483089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is 5q deletion in de novo Acute Myelogenous Leukemia (AML) with excess blasts a surrogate marker for the cryptic t(7;21)(p22;q22)? A case report and review of literature.
    Johnston RD; Sayedian FH; Mendiola C; Ehman W; Ortega V; Velagaleti GVN
    Cancer Genet; 2022 Apr; 262-263():30-34. PubMed ID: 34974291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein E; Weber UM; Gore S
    Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
    [No Abstract]   [Full Text] [Related]  

  • 17. Hybrid leukemia and the 5q-abnormality.
    Sun G; Wormsley S; Sparkes RS; Naeim F; Gale RP
    Leuk Res; 1991; 15(5):351-6. PubMed ID: 2046386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
    Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.